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Abstra ct
Backgro und: Heart failure (HF) is a common complication of cardiovascular diseases, and 
patients with HF remain largely under the care of primary care physicians (GPs). Therefore, 
the goal of the study presented was to assess the GPs’ knowledge of chronic HF guidelines in 
regards to their professional experience.
Methods and results: In 2008, during a nationwide educational project on HF manage-
ment, 15 courses for GPs were conducted. Before the training, physicians fi lled out a standar-
dized questionnaire about the diagnosis and treatment of HF. The answers were assessed in 
a three age-group of respondents: 24–39 years (n = 142), 40–55 years (n = 316), 56 years and 
above (n = 156). Of 614 physicians, 97% indicated echocardiography as obligatory diagnostic 
procedure in HF diagnosis. The oldest GPs more frequently pointed to the role of chest X-ray 
(63%, p < 0.001) and electrocardiography (32%, p < 0.001) in exclusion of systolic HF. There 
was a signifi cant reverse relationship between physicians’ age and their declarations in pre-
scription of angiotensin II receptor blockers (p = 0.007; contingency coeffi cient, Cc= 0.13) and 
b-blockers (p = 0.01; Cc = 0.12) in patients with advanced HF (NYHA III–IV), and positive 
relation between application of spironolactone (p = 0.007; Cc = 0.13) and digitalis (p < 0.001; 
Cc = 0.16) in patients of NYHA class I–II. The new generation b-blockers (bisoprolol, 
carvedilol, nebivolol) were more frequently prescribed by the youngest physicians (respectively: 
98%, 96%, 58%) compared to the oldest group (respectively: 88%, 87%, 50%; p < 0.05). 
Conclusions: The study revealed age of GPs to be inversely related to their knowledge of HF 
guidelines and potential therapeutic decisions in management of HF patients and support of 
the need of continuing medical education. (Cardiol J 2013; 20, 4: 356–363)
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Introduction
Heart failure (HF) is currently one of the most 
common and rising chronic diseases in developed 
countries. Total percentage of people with HF 
reaches 0.4–2% in Europe [1] and among people 
over the age of 75 it exceeds 10% [2]. In European 
Union countries the number of patients surpasses 
15 million [3] and in Poland 1 million [4]. The study 
conducted in Poland in 2005 showed that most of 
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the patients with HF were under the care of pri-
mary care physicians (GPs) [5]. 
The randomized, multicentre study SHAPE 
(the Study group on Heart Failure Awareness and 
Perception in Europe), carried out in 2008, also in 
Poland, showed poor adherence to guideline-re-
commended management strategies of HF, espe-
cially in the group of internists, geriatricians and 
GPs [6]. Similarly, recently published data of the 
Polish study, assessing the knowledge of 125 GPs, 
demonstrated that a satisfactory adherence to 
Polish guidelines-management of hypertension 
characterized 51% GPs [7]. 
To our best knowledge, the relationship be-
tween a physician’s age or years of professional 
experience has not been studied yet. Therefore, the 
aim of the presented study is to assess whether age 
of GPs is associated with their knowledge of chro-
nic HF guidelines and is it related with therapeutic 
decision making in management of HF patients. 
Methods
In 2008, a Polish nationwide education project 
for GPs about guideline-recommended mana-
gement strategies in HF was conducted. It was 
a multicenter project, and a training program was 
developed in collaboration with The College of 
Family Physicians in Poland. 
The trainings’ schedule and agenda were 
available on the offi cial website of the College. 
The project was also promoted in the educational 
journal of Polish GPs and in a newsletter sent pe-
riodically to GPs. Recruitment for participation in 
training was conducted through the website.
The courses were conducted in 15 provinces in 
Poland from 15 September to 30 November 2008, 
and the study involved 872 GPs. At the beginning 
of each training, participants fi lled out a standar-
dized questionnaire consisting of 19 questions 
— 5 of them related to the diagnosis and 14 to the 
recommendations from 2008 on the treatment of 
chronic HF. There were 16 single and 3 multiple 
choice type questions with predefi ned answers.
The answers were assessed according to the 
guidelines of European Society of Cardiology (ESC) 
published in 2005 [8]. The analysis was performed in 
three age-groups of physicians: 24–39 years (n = 142), 
40–55 years (n = 316) and 56 and more years old 
(n = 156). 
The database management and statistical ana-
lysis were performed using SAS software, version 
9.2 (SAS Institute Inc, Cary, NC) licensed to the 
Jagiellonian University. 
Descriptive statistics involved mean ± stan-
dard deviations (SD) and percentages. Distribu-
tion of continuous variables was determined by 
Shapiro-Wilk test. One-way ANOVA was used for 
comparisons of continuous variables between the 
age-groups and contingency coeffi cient (Cc) to de-
termine association between categorical variables. 
Results
Out of 872 GPs who attended all training cour-
ses, 614 completed and returned the questionnai-
res (70%). The mean age of the respondents was 
48.0 ± 11.5 ranging from 24 to even 90 years, 76% 
of them were women.
Heart failure diagnosis and classifi cation
More than 96% of GPs from each age-group 
indicated echocardiography as a procedure essen-
tial to diagnose HF (Table 1). The oldest physicians 
more frequently than the younger ones pointed 
to the role of chest X-ray (63%, p < 0.001) and 
electrocardiography (32%, p < 0.001) in exclusion 
of systolic HF. On the other hand, the younger 
physicians signifi cantly more likely indicated left 
ventricular ejection fraction (LVEF), above 50%, 
without mitral insuffi ciency as exclusion criterion 
(Table 1). 
Only 23% of GPs recognized and declared the 
application of current HF classifi cation as systolic 
and diastolic (with preserved LVEF). This classi-
fi cation has not been used by 72% of physicians, 
despite the knowledge of this classifi cation. Ho-
wever, the New York Heart Association (NYHA) 
scale was used on everyday practice by almost all 
the GPs (94%); only 1% of GPs did not apply any 
of these classifi cations.
Heart failure pharmacotherapy 
For HF patients with NYHA class I or II and 
sinus rhythm, angiotensin converting enzyme in-
hibitors (ACE-I), angiotensin II receptor blockers 
(ARB), b-blockers, and diuretics were recommen-
ded by physicians from different age groups with 
similar frequency (Table 2). Older physicians signi-
fi cantly more frequently indicated spironolactone, 
digitalis, and calcium channel blockers as preferred 
drugs (Table 2).
In patients with advanced HF (NYHA class III 
to IV), the respondents favored diuretics, spirono-
lactone and digitalis without signifi cant differences 
between the age-groups (Table 2). Moreover, older 
GPs, compared to younger, declared less frequent 
use of ARB and b-blockers. Younger GPs were 
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more likely to use sartans in their patients with HF 
because of intolerance of ACE-I (age 24–39: 97.0%; 
40–55: 89.4%; 56–90 : 87.1%), whereas older GPs 
more often administered this class of drugs as 
a continuation of therapy (age 24–39: 22.0%; 40–55: 
29.9%; 56–90: 36.7%).
Among ACE-I recommended by the ESC gu-
idelines were enalapril, captopril and lisinopril. The 
proper recommended dose of enalapril (10 mg twice 
a day) was indicated by 17.0% of GPs at age 24–39; 
32.1% at age 40–55; 13.7% at age 56–90 (p = 0.016). 
The target dose of captopril (25–50 mg three times 
a day) indicated 13.4% at age 24–39; 21.5% at age 
40–55 and 5.3% at age 56–90. Lisinopril (5–20 mg 
twice a day) had been chosen in a optimal dose by 
13.6% GPs aged 24–39, 24.4% aged 40–55 and 9.9% 
aged 56–90. Use of maximal guideline-recommen-
ded doses of ACE-I in HF patients declared 41.1% 
of young, 37.1% of middle-aged and 29.6% of older 
GPs (Table 3). In general, more than half of the 
youngest GPs and approximately 78% GPs from the 
oldest group adjusted dosage of ACE-I according to 
HF severity (Table 3).
Declared use of b-blockers, recommended 
by the guidelines inversely correlated with the 
age of the respondents. The percentage (respec-
tively for three age categories from the youngest 
to the oldest) was for: bisoprolol: 97.9%; 93.2%; 
88.1%; p = 0.005; carvedilol: 95.7%; 91.9%; 87.4%; 
p = 0.036; metoprolol: 90.1%; 89.6%; 84.1%; 
p = 0.17 and fro nebivolol: 58.2%; 44.3%; 50.3%; 
p = 0.023. Atenolol has been indicated by 15.2% of 
the oldest GPs, 13.0% of middle-aged and 2.1% of 
the youngest ones (p < 0.001), whereas propranolol 
was used respectively by 6.6%, 5.7% and 1.4% GPs 
(p = 0.077). As for the maximum recommended 
doses of b-blockers GPs most often pointed to: 
bisoprolol 10 mg daily, carvedilol 2 × 25 mg per 
day, metoprolol 200 mg and nebivolol 10 mg per 
day. The younger GPs signifi cantly more frequently 
indicated the proper target doses of the b-blockers 
than the older (Fig. 1). Most older GPs declared 
to adjust the dose of b-blockers according to the 
severity of HF and blood pressure level, while the 
youngest GPs more frequently declared use of 
maximum doses of b-blockers (Table 3).
Almost all of the respondents (95.7%) re-
commended diuretics in patients with fluid re-
tention and up to 43.0% of GPs used them in 
all patients with HF, more frequently middle-
-aged physicians (40.1%) and older physicians 
(59.0%) compared with the young ones (29.8%, 
p < 0.001). Diuretics, as the first drug for the 
treatment of HF, were chosen by 46.9% of GPs 
at age 56–90, 33.7% of GPs at age 40–55, and 
by 17.9% of the youngest GPs (p < 0.001). 
The physicians usually started treatment with 
low doses of loop diuretics (79.0%) or low doses 
Table 1. Primary care physicians’ opinion about heart failure diagnosis.
N valid Physicians’ age (n = 614) P Cc
24–39
(n = 142)
40–55
(n = 316)
≥ 56
(n = 156)
Age (mean ± SD) 614 32.9 ± 4.5 47.7 ± 4.7 62.6 ± 6.3 < 0.001 –
Female (%) 610 81.7 78.2 65.4 0.004 –
Diagnosis of heart failure:
Echocardiography is 
obligatory (%)
613 97.9 96.5 97.4 0.685 0.035
Results excluding of systolic 
heart failure:
Chest X-ray (%) 591 34.3 50.5 62.7 < 0.001 0.195
ECG without signs 
of MI (%)
591 9.5 13.3 32.0 < 0.001 0.228
LVEF about 50% 
with moderate MVI (%)
591 37.2 28.2 34.0 0.138 0.082
LVEF about 50% 
without MVI (%)
591 64.2 61.1 47.7 0.007 0.129
Electrolytes/serum 
creatinine monitoring 
every 3 to 6 months
598 58.3 61.0 59.1 0.266 0.112
Cc — contingency coefficient; MI — myocardial infarction; LVEF — left ventricular ejection fraction; MVI — mitral valve insufficiency; 
p — value for ANOVA trend or c2 for table
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of thiazide diuretics (78.2%), and there were no 
significant differences in age-group comparisons. 
The respondents most often declared b-bloc-
kers, ACE-I and sartans as drugs with potential to 
prolong the life of patients with HF (Table 4). The 
younger GPs more often recommended digitalis as 
the drug reducing HF symptoms, whereas the older 
GPs more often believed that digitalis can improve 
prognosis (Table 4). About half of the surveyed 
GPs had a diffi culty in defi ning the role of calcium 
channel blockers in the treatment of HF. Apart 
from that, 15% of the oldest GPs expected that 
long-lasting nitroglycerine will improve prognosis 
of patients with HF (Table 4).
Discussion
Our study indicated generational differences 
among Polish GPs in approach to the existing 
guideline recommendations on HF diagnosis and 
Table 4. Physicians’ perception of expected results of pharmacotherapy in heart failure (HF). 
Expected
results in HF
N valid Physicians’ age P Cc
24–39 40–55 ≥ 56
ACE-I Symptoms 573 73.7 78.6 71.2 0.202 0.075
Prognosis 573 94.9 85.2 79.5 < 0.001 0.157
Indecision 573 0.0 1.7 2.1 0.269 0.068
ARB Symptoms 554 67.2 70.4 59.6 0.086 0.094
Prognosis 554 80.6 64.8 65.4 0.003 0.143
Indecision 554 3.7 7.8 9.6 0.160 0.081
Beta-blockers Symptoms 568 66.9 71.5 63.9 0.247 0.070
Prognosis 568 90.4 81.3 70.8 0.0002 0.173
Indecision 568 0.7 3.8 4.2 0.175 0.078
Diuretics Symptoms 575 97.0 95.9 93.2 0.256 0.069
Prognosis 575 16.3 26.5 34.3 0.003 0.142
Indecision 575 0.0 1.0 0.0 0.237 0.071
Spironolactone Symptoms 565 77.2 85.0 81.7 0.141 0.083
Prognosis 565 59.6 55.1 47.2 0.107 0.089
Indecision 565 0.7 2.8 2.8 0.377 0.059
Digitalis Symptoms 556 92.5 91.6 83.3 0.016 0.121
Prognosis 556 3.8 8.1 15.9 0.002 0.151
Indecision 555 6.1 7.0 8.7 0.694 0.036
Ca-blockers Symptoms 486 41.7 40.4 38.8 0.904 0.020
Prognosis 486 15.0 13.1 27.3 0.002 0.156
Indecision 486 51.7 53.9 42.2 0.102 0.096
Long-lasting nitroglycerine Symptoms 533 70.5 65.7 57.1 0.068 0.100
Prognosis 533 3.9 8.5 15.0 0.006 0.137
Indecision 534 28.7 29.0 34.6 0.468 0.053
Cc — contingency coefficient; ACE-I — angiotensin converting enzyme inhibitors; ARB — angiotensin II receptor blocker; Ca-blocker — 
calcium channel blocker; p — value of c2 for table
Figure 1. Physicians’ awareness of b-blockers’ recom-
mended doses in management of heart failure patients; 
Cc — contingency coefficient.
Nebivolol
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0
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treatment. At the time, the younger family physi-
cians demonstrated better knowledge and adheren-
ce to ESC recommendations than the older ones. 
Echocardiography criteria of diagnosis HF 
were frequently more indicated by younger physi-
cians, while the oldest physicians were more likely 
to base their diagnoses on chest X-ray and elec-
trocardiography results. In the IMPROVEMENT 
project (1999–2000), the fi rst large study assessing 
HF patients management, only 18% of GPs indi-
cated echocardiography as a necessary diagnostic 
procedure in HF [9]. Similarly, in a European Heart 
Failure Study (EHFS) I and II, conducted from 2000 
to 2001 in 24 European countries, it was found that 
in some centers cardiac ultrasound was performed 
in 20–30% patients with suspected or diagnosed HF, 
and the average rate of echocardiography was 58% 
[10]. Our previously published data has shown that 
approximately 50% of HF patients in primary set-
tings were not examined by echocardiography [11]. 
More than 10 years after the IMPROVEMENT 
study, our results show that 96% of GPs are aware 
of the role of echocardiography in the diagnostic 
process of HF. However, almost half of the respon-
dents (mainly older GPs) incorrectly exclude HF on 
the basis of normal cardiac size in patients’ chest 
X-ray, as normal results of radiological examination 
of the chest are present in 1/3 of patients with HF, 
such as with preserved left ventricular function 
or in restrictive cardiomyopathy [12]. In recently 
published Italian study from 2011, 1078 GPs under 
the age of 40 were the group which could choose 
the most accurate diagnoses and treatment of car-
diovascular diseases [13].
We also demonstrated that treatment strate-
gies declared by younger doctors are more consi-
stent with ESC guidelines. Physicians’ awareness 
and their compliance with guideline-recommended 
strategies of HF pharmacotherapy has signifi can-
tly improved within the last 10 years. Beginning 
from the aforementioned IMPROVEMENT study, 
ACE-I were used only in 65% of patients with HF 
and b-blockers in 34% of them and generally their 
dosage was insuffi cient [9–14]. The study EHFS I 
and II revealed that among patients with suspected 
or previously diagnosed HF, ACE-I were used only 
in 62% and b-blockers only in 37% of the patients 
[10]. In the same study 90% of patients with LVEF 
below 40% were receiving ACE-I, but b-blockers 
were used only in 49% of them.
In our previously published data from the 
POLKARD study, ACE-I were taken by 81.0% and 
b-blockers by 68.3% of HF patients treated by GPs 
[11]. Based on physicians’ declaration, presented in 
this study, the GPs awareness of HF pharmacothe-
rapy and their compliance with guidelines seems 
to improve systematically. 
The SHAPE study has shown that 62% GPs 
in Poland (in comparison to 42% GPs in Europe) 
declared to prescribe ACE-I in patients with HF 
[6]. In comparison, 78% of cardiologists and 79% 
of internists and geriatricians in Poland declared 
to use ACE-I in over 90% of patients with HF [6].
A cross-sectional analysis that was performed 
with the data of 167 HF cases with documented left 
ventricular systolic dysfunction, enrolled in 37 GP 
practices in Germany showed that the proportion 
of target doses reached for ACE-I/sartan was 16% 
and for b-blockers only 8% [15]. When adjusted for 
relative contraindications, the percentage of target 
doses increased to 49% and 46%, respectively. 
These data are comparable with our physicians’ 
declarations in regards to use of maximal doses of 
the b-blocker, but maximal doses, both of ACE-I 
and b-blockers, were more likely used by younger 
physicians than the older. 
In retrospective cohort study performed in 
163 GPs in Great Britain (2001–2006), on 9311 HF 
patients only 36.6% were prescribed a b-blocker 
and 68% of them had a b-blocker currently re-
commended in ESC guidelines [16]. In our study, 
most physicians declared the use of guideline-
-recommended b-blockers, however up to 15% of 
physicians (mainly older GPs) continue to prescribe 
older class agents.
High position among the drugs recommended 
by GPs took diuretics. As many as 80.7% of older 
physicians declared to prescribe these drugs alre-
ady in NYHA class I and II. The MAHLER study 
(Medical Management of Chronic Heart Failure 
in Europe and its Related Costs) assessed the 
treatment of patients by the randomly selected 
European cardiologists. In this study diuretics 
were most commonly prescribed and 79% of pa-
tients with HF, mainly class NYHA II and III, were 
receiving them [17]. 
In comparison to guidelines given by European 
and Polish Society of Cardiology, our study showed 
that GPs declared to prescribe spironolactone very 
often in HF cases. Half of older GPs declared the 
use of spironolactone in HF classifi ed as NYHA I 
and II, while it should be limited in this stage to 
postinfarctial HF patients only. Earlier Polish study 
(2004, PolKARD-SPOK) revealed that 21.9% pa-
tients with HF in class NYHA II–IV were treated 
with spironolactone [18]. It is possible that within 
a few years between these two studies the GPs’ 
awareness increased. However, we cannot compare 
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these results because of the signifi cant differences 
in study protocols. 
Use of digitalis was declared in our study by 5% of 
the youngest and 20% of the oldest GPs for mild and 
moderate HF patients (NYHA class I–II). The ESC 
recommendations (from 2005) said unequivocally that 
digitalis in this group of patients should be used pri-
marily in the case of co-occurrence of atrial fi brillation 
(AF). We could not verify the indications for digitalis, 
however epidemiologic data shows that the prevalence 
of AF in HF population is 5–10% in NYHA class I, 
25% in classes II–III, 50% in class IV [19–21]. These 
results suggest that our senior physicians are more 
likely used to the older agents, such as diuretics and 
digoxin, also in HF patients in NYHA class I and II.
In 2011, the study results of 25,00 family GPs 
in Germany were published. The physicians fi lled 
out questionnaires about the HF diagnoses and 
therapies in their medical practices [22]. Of all the 
physicians surveyed, 40% presented acceptable 
knowledge about the guidelines of cardiovascular 
diseases [22], however, only 24% of physicians cor-
rectly answered the question about the treatment 
of patients with HF in accordance with the current 
recommendations [22]. 
Within last several years the quality of care for 
patients with HF has signifi cantly improved and 
the percentage of patients treated in accordance 
with current standards has increased [9–11]. To 
keep this benefi cial process it seems important 
to continue educational programs among primary 
care physicians. Wide accessibility of the special-
ly prepared educational materials based on the 
guideline recommendations, including knowledge 
transformation to more affordable and unequivocal 
communication seems to be crucial in improving 
physicians’ awareness and perceptions of the gu-
idelines. Over the past two decades the Canadian 
experiences with implementation of the Canadian 
Hypertension Education Program (CHEP) has fully 
confi rmed such an approach [23, 24].
Limitations of the study
Our study should be interpreted within the 
context of its possible limitations. The data ob-
tained from GPs, relating to the management of 
patients with HF, was based solely on their decla-
rations in the structured questionnaire. Therefore, 
the results of this study cannot be directly compa-
red with studies targeted at evaluation of diagnostic 
and therapeutic procedure in real practice.
Our questionnaire was conducted among par-
ticipants in training sessions, so by defi nition it 
was not a representative sample of GPs in Poland. 
However, the nationwide scope of the study and 
a large number of physicians surveyed makes the 
study a valuable source of information about kno-
wledge of current HF guidelines.
Conclusions
Primary care physicians’ awareness of HF re-
commendations increases, however our study indi-
cated some discrepancies in guidelines knowledge 
between younger and older physicians. Various 
educational activities focusing on the knowledge 
translation might be helpful in improving quality 
of care for patients with HF. 
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